Michael Groaning

Michael Groaning serves as Chief Scientific Officer at Soricimed Biopharma Inc. since September 2025, where responsibilities include leading precision oncology drug research and development, particularly for TRPV6-targeted RLT candidates. Prior roles include Vice President and Global Program Leader at Fusion Pharmaceuticals, directing program strategy and aligning project goals with business needs from January 2024 to August 2025, and Global Medical Affairs Lead at Amgen, focusing on prostate cancer from January 2021 to January 2024. Earlier experience encompasses strategic development at Advanced Accelerator Applications, where Michael developed US disease strategies, and senior roles at Endocyte and Roche Pharmaceuticals. Academic credentials include a Master of Public Health from Tufts University, a PhD in Organic Chemistry from Colorado State University, and postdoctoral studies at ETH Zürich.